Source: Annual Congress 2001 - Interstitial and other respiratory diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. N. Vasilyev, L. V. Ozerova, I. P. Zaitseva (Moscow, Russia). Outcomes of fibrosing alveolitis. Long-term follow-up. Eur Respir J 2001; 16: Suppl. 31, 2639

Member's Comments

No comment yet.

Related content which might interest you: 15-year follow-up of patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002 Cryptogenic fibrosing alveolitis (CFA) in post-delivery period - the results of the long-term study Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Long-term follow-up of patients with pulmonary sarcoidosis Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Specific features of the course of cryptogenic fibrosing alveolitis in pregnancy Source: Eur Respir J 2001; 18: Suppl. 33, 150s Year: 2001 B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Safety and efficacy of prolonged treatment of fibrosing alveolitis in scleroderma with cyclophosphamide Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 Clinical presentation and outcome of fibrosing mediastinitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Long-term outcome after infantile bronchiolitis and pneumonia: a prospective 20-year follow-up Source: Annual Congress 2003 - New perspectives in bronchiolitis Year: 2003 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Histopathological findings of biopsies from patients with extrinsic allergic alveolitis (hipersensitivity pneumonia) in subacute or chronic phase Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias Source: ERJ Open Res, 5 (2) 00045-2019; 10.1183/23120541.00045-2019 Year: 2019 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical features of pulmonary aspergillosis in patients with chronic fibrosing interstitial pneumonia Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Childhood sarcoidosis: long-term follow-up Source: Eur Respir J 2008; 31: 592-598 Year: 2008 Lung cancer in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 The features of the course of cryptogenic fibrosing alveolitis in women Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002